Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND3 | P30281 | 2/20 | 0.49 |
| ▸ | CCNK | O75909 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 2/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26977050 | 0.90 | SYK (0.49) | CCND3CDK2JAK2BRD4MAPT | |
| SCHEMBL26980153 | 0.86 | CCNK (0.53) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL30671838 | 0.84 | JAK2 (0.48) | CDK2JAK2FLT3BRD4MAPT | |
| SCHEMBL26977065 | 0.84 | JAK2 (0.48) | CDK2JAK2FLT3BRD4MAPT | |
| SCHEMBL26980738 | 0.82 | BTK (0.62) | JAK2FLT3JAK1TYK2JAK3 | |
| SCHEMBL29929709 | 0.82 | BTK (0.62) | JAK2FLT3JAK1TYK2JAK3 | |
| SCHEMBL27240960 | 0.80 | JAK2 (0.41) | CDK2CDK9JAK2MAPK1JAK1 | |
| SCHEMBL27241026 | 0.78 | NUAK1 (0.48) | JAK1JAK3FGFR1IGF1R | |
| SCHEMBL27240782 | 0.78 | BTK (0.56) | CCND3CCNKCCNA2CDK2CDK9 | |
| SCHEMBL26977295 | 0.77 | IGF1R (0.43) | CDK2CDK9JAK2MAPK1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-4297873-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | Tyra Biosciences, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2022182972-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | DPYD, TYMP, TYMS | CCND3 410/4885CCNK 352/4885CCNA2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.